Aphexda
(Motixafortide)ApprovedPeptide
Alnylam PharmaceuticalsMotixafortide is used alongside filgrastim to prepare cells for stem cell transplantation in multiple myeloma patients. It works by mobilizing stem cells into the bloodstream so they can be collected for transplant purposes.[2] Aphexda is currently approved and in use across 4 indications[4].[1]
Aphexda is one of 132 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Approved.
4
Indications
7
Total Trials
5
Active Trials
131
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Aphexda
Alnylam PharmaceuticalsApproved
Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease2 trials
Pancreatic Adenocarcinoma1 trial
Regulatory
FDA Approval Timeline[5]
Sep 8, 2023
APHEXDA
NDA NDA217159
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aphexda drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Motixafortide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]